These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 25465343)

  • 1. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
    Peixoto RD; Kumar A; Speers C; Renouf D; Kennecke HF; Lim HJ; Cheung WY; Melosky B; Gill S
    Clin Colorectal Cancer; 2015 Mar; 14(1):25-30. PubMed ID: 25465343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
    Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
    Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care.
    Yu S; Shabihkhani M; Yang D; Thara E; Senagore A; Lenz HJ; Sadeghi S; Barzi A
    Clin Colorectal Cancer; 2013 Dec; 12(4):275-9. PubMed ID: 24188686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to adjuvant chemotherapy and survival outcomes among patients with stage 2 to 3 rectal cancer treated with preoperative chemoradiation.
    Gresham G; Cheung WY; Speers C; Woods R; Kennecke H
    Clin Colorectal Cancer; 2015 Mar; 14(1):41-5. PubMed ID: 25548075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
    Ejaz A; Casadaban L; Maker AV
    J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
    Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
    Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
    Tougeron D; Mouillet G; Trouilloud I; Lecomte T; Coriat R; Aparicio T; Des Guetz G; Lécaille C; Artru P; Sickersen G; Cauchin E; Sefrioui D; Boussaha T; Ferru A; Matysiak-Budnik T; Silvain C; Karayan-Tapon L; Pagès JC; Vernerey D; Bonnetain F; Michel P; Taïeb J; Zaanan A
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26839356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
    Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands.
    van Gils CW; Koopman M; Mol L; Redekop WK; Uyl-de Groot CA; Punt CJ
    Acta Oncol; 2012 Jan; 51(1):57-64. PubMed ID: 22122695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.
    Aspinall SL; Good CB; Zhao X; Cunningham FE; Heron BB; Geraci M; Passero V; Stone RA; Smith KJ; Rogers R; Shields J; Sartore M; Boyle DP; Giberti S; Szymanski J; Smith D; Ha A; Sessions J; Depcinski S; Fishco S; Molina I; Lepir T; Jean C; Cruz-Diaz L; Motta J; Calderon-Vargas R; Maland J; Keefe S; Tague M; Leone A; Glovack B; Kaplan B; Cosgriff S; Kaster L; Tonnu-Mihara I; Nguyen K; Carmichael J; Clifford L; Lu K; Chatta G
    BMC Cancer; 2015 Feb; 15():62. PubMed ID: 25884851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
    Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A
    J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?
    Bayraktar UD; Chen E; Bayraktar S; Sands LR; Marchetti F; Montero AJ; Rocha-Lima CM
    Cancer; 2011 Jun; 117(11):2364-70. PubMed ID: 24048783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.
    Kim CA; Spratlin JL; Armstrong DE; Ghosh S; Mulder KE
    Clin Colorectal Cancer; 2014 Sep; 13(3):199-206. PubMed ID: 25088184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Benefit of adjuvant 5-fluorouracil based chemotherapy for colon cancer: a retrospective cohort study].
    Mondaca S; Villalón C; Leal JL; Zúñiga Á; Bellolio F; Padilla O; Palma S; Garrido M; Nervi B
    Rev Med Chil; 2016 Feb; 144(2):145-51. PubMed ID: 27092667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.